Evidence map›Paper›PMID 21421992›Full record

ArticleJournal of lipid research2011

Ubiquitination regulates the assembly of VLDL in HepG2 cells and is the committing step of the apoB-100 ERAD pathway.

Eric A Fisher, Neeraj A Khanna, Roger S McLeod

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Ubiquitin ligases in cholesterol metabolism.Diabetes & metabolism journal · 2014
    Review
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Eric A FisherDepartment of Biochemistry & Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 1X5.
Neeraj A KhannaDepartment of Biochemistry & Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 1X5.
Roger S McLeodDepartment of Biochemistry & Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 1X5. Electronic address: rmcleod2@dal.ca.
Dalhousie University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apolipoprotein B-100 (apoB-100) is degraded by endoplasmic reticulum-associated degradation (ERAD) when lipid availability limits assembly of VLDLs. The ubiquitin ligase gp78 and the AAA-ATPase p97 have been implicated in the proteasomal degradation of apoB-100. To study the relationship between ERAD and VLDL assembly, we used small interfering RNA (siRNA) to reduce gp78 expression in HepG2 cells. Reduction of gp78 decreased apoB-100 ubiquitination and cytosolic apoB-ubiquitin conjugates. Radiolabeling studies revealed that gp78 knockdown increased secretion of newly synthesized apoB-100 and, unexpectedly, enhanced VLDL assembly, as the shift in apoB-100 density in gp78-reduced cells was accompanied by increased triacylglycerol (TG) secretion. To explore the mechanisms by which gp78 reduction might enhance VLDL assembly, we compared the effects of gp78 knockdown with those of U0126, a mitogen-activated protein kinase/ERK kinase1/2 inhibitor that enhances apoB-100 secretion in HepG2 cells. U0126 treatment increased secretion of both apoB100 and TG and decreased the ubiquitination and cellular accumu-lation of apoB-100. Furthermore, p97 knockdown caused apoB-100 to accumulate in the cell, but if gp78 was concomitantly reduced or assembly was enhanced by U0126 treatment, cellular apoB-100 returned toward baseline. This indicates that ubiquitination commits apoB-100 to p97-mediated retrotranslocation during ERAD. Thus, decreasing ubiquitination of apoB-100 enhances VLDL assembly, whereas improving apoB-100 lipidation decreases its ubiquitination, suggesting that ubiquitination has a regulatory role in VLDL assembly.

Indexed as

Apolipoprotein B-100Cholesterol, VLDLAdenosine TriphosphatasesButadienesEndoplasmic ReticulumEnzyme InhibitorsGene SilencingHep G2 CellsHumansIsotope LabelingMitogen-Activated Protein Kinase KinasesNitrilesNuclear ProteinsProteasome Endopeptidase ComplexProtein BiosynthesisReceptors, Autocrine Motility FactorAdenosine TriphosphatasesAMFR protein, humanApolipoprotein B-100ButadienesCholesterol, VLDLEnzyme InhibitorsMitogen-Activated Protein Kinase KinasesNitrilesNuclear Proteinsp97 ATPaseProteasome Endopeptidase ComplexReceptors, Autocrine Motility FactorReceptors, CytokineRNA, Small InterferingTriglyceridesU 0126UbiquitinUbiquitin-Protein Ligases

Identifiers

PMID21421992
PMCPMC3090238
OpenAlexW2114081556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.